Geoffrey Dow Purchases 7,350 Shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) CEO Geoffrey Dow purchased 7,350 shares of the stock in a transaction on Friday, June 12th. The stock was acquired at an average price of $1.38 per share, with a total value of $10,143.00. Following the completion of the acquisition, the chief executive officer directly owned 24,131 shares of the company’s stock, valued at approximately $33,300.78. This represents a 43.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

60 Degrees Pharmaceuticals Price Performance

Shares of 60 Degrees Pharmaceuticals stock traded up $0.13 during trading hours on Monday, hitting $1.49. The company’s stock had a trading volume of 85,627 shares, compared to its average volume of 2,528,288. 60 Degrees Pharmaceuticals Inc. has a 12 month low of $1.22 and a 12 month high of $10.77. The stock has a 50 day moving average of $1.60 and a 200 day moving average of $2.51. The company has a market capitalization of $3.96 million, a PE ratio of -0.17 and a beta of 2.65.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.52). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.44 million. Equities analysts expect that 60 Degrees Pharmaceuticals Inc. will post -3.3 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Ascendiant Capital Markets decreased their price objective on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating for the company in a report on Friday, May 22nd. HC Wainwright downgraded 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, May 20th. Finally, Wall Street Zen downgraded 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 12th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.85.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.